CGT’s Next Obstacle: Securing the Leukapheresis Supply Chain

Why It Matters

Without a resilient leukapheresis supply chain, cell‑gene programs risk delayed launches, limited patient enrollment, and higher development costs, threatening the commercial viability of next‑generation therapies.

Key Takeaways

• Leukapheresis capacity lags behind growing CAR‑T demand.
• Academic centers dominate, limiting rural patient access.
• Vendor qualification requires accreditation, SOPs, capacity, logistics.
• Mobile collection units add surge capacity and geographic reach.
• Early collaboration reduces variability and accelerates time‑to‑market.

Pulse Analysis

The rapid rise of cell and gene therapies has exposed a hidden weakness: the leukapheresis supply chain. While autologous CAR‑T programs have flourished in oncology, developers are now targeting larger, chronic indications that demand far more starting material. Existing apheresis facilities are clustered in metropolitan academic hospitals, creating a capacity ceiling that forces patients to travel long distances and introduces scheduling bottlenecks. This geographic concentration also amplifies quality variability, as differing site practices affect T‑cell fitness and downstream manufacturing yields.

Addressing these constraints requires a shift from treating leukapheresis as an operational afterthought to a strategic asset. Robust vendor qualification—encompassing FACT/AABB accreditation, standardized operating procedures, proven throughput, and end‑to‑end chain‑of‑custody controls—helps align collection sites with manufacturing expectations. Early‑stage collaboration enables data‑driven feedback loops, reducing variability and shortening vein‑to‑vein times. For allogeneic programs, reliance on a limited donor pool raises product consistency concerns, prompting the industry to explore super‑donor models and diversified donor networks.

Mobile leukapheresis units represent a pragmatic innovation that bridges capacity gaps while extending access to underserved regions. Designed as GMP‑compliant, these units replicate brick‑and‑mortar quality systems, allowing a single governance framework to oversee multiple collection points. By deploying mobile platforms, sponsors can surge capacity during trial enrollment peaks, improve patient diversity, and mitigate geographic barriers. Ultimately, integrating mobile solutions with rigorous vendor standards transforms a supply‑chain bottleneck into a competitive advantage, accelerating the commercialization of next‑generation cell therapies.